From UBS conference, management reiterated $6-6.50 EPS, Acthar rev > $1B, FCF $500M, VTS-270 phase 3 finished and filing NDA. Acthar data readouts coming in next 2 weeks. Looking to drive up Acthar volume with clinical data. Inomax doing well. Working closely with FDA on Stannsoporfin for elevated blood bilirubin in neonates. Any competitions for Acthar will have a long and tough roads for them. It will be like 5-7 years down the road for them if they have enough money for it. Debts delevering, shares repurchase. Oh yeah, short-interest 39% of float.
$MNK From CEO Trudeau. We have several additional data readouts expected beginning the second quarter of 2018. And we continue to believe that Acthar net sales for 2018 will be in excess of $1 billion.